BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Non-GAAP Adjusted Cost of Sales — Product by Quarter
Non-GAAP Adjusted Cost of Sales — Product ($M) ($M)
BeOne Medicines Non-GAAP Adjusted Cost of Sales — Product: $167M in Q2 2026, up 8.3% from a year earlier.
Latest, Q2 2026
167
Period ended Jun 30, 2026
Change on a year earlier
+8.3%
155 in Q2 2025
History
15 quarters
Since Q4 2022
Sources
11
Documents cited below
Where the Q2 2026 figure comes from
“|| Adjusted cost of sales - products | $ | 167,418 | $ | 154,643 | $ | 328,565 | $ | 315,859”
Source: Form 8-K (filed 2026-08-05) ↗
Reported in Form 8-K EX-99.1 Non-GAAP Reconciliation Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP Adjusted Cost of Sales — Product ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 167 | +8.3% | Form 8-K (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 161 | 0.0% | Form 8-K (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 137 | -2.7% | Form 8-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 191 | +27.4% | Form 8-K (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 155 | +15.2% | Form 8-K (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 161 | +32.8% | Form 8-K (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 141 | +37.4% | Form 8-K (filed 2025-02-27) ↗ |
| Q3 2024 | Sep 30, 2024 | 150 | +60.9% | Form 8-K (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 134 | +44.4% | Form 8-K (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 121 | +54.1% | Form 8-K (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 103 | +41.3% | Form 8-K (filed 2024-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 93.0 | – | Form 8-K (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 93.0 | – | Form 8-K (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 78.8 | – | Form 8-K (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 72.7 | – | Form 8-K (filed 2024-02-26) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Non-GAAP Adjusted Cost of Sales — Product ($M), quarterly Q4 2022–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/adj-cogs-prod
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.